What Agilent Technologies does

Agilent Technologies, Inc. is a publicly traded (NYSE: A) analytical instrumentation and life sciences company headquartered in Santa Clara, California, spun off from Hewlett-Packard in 1999. With approximately 18,000 employees, FY25 revenue of US $6.95B, and support coverage spanning 285,000+ laboratories across 110 countries, Agilent supplies high-precision analytical instruments — gas chromatography (8890B/8860B/8850 GC), liquid chromatography (Infinity III LC Series), mass spectrometry (7010D GC/MS, LC/MS, Agilent 9500 Triple Quadrupole ICP-MS), molecular spectroscopy, cell analysis (Seahorse, RTCA, BioTek), capillary electrophoresis, and GPC/SEC — alongside pathology and digital diagnostics (Dako Omnis staining, PD-L1 IHC 22C3 pharmDx, S540MD slide scanner, Avida NGS workflows), software and informatics (OpenLab CDS, OpenLab Sync, MassHunter, CrossLab Connect, iLab, SLIMS, DakoLink), and a specialty CDMO business (BIOVECTRA oligonucleotide GMP manufacturing).

The company operates a hybrid razor-and-blade revenue model combining capital equipment sales with high-recurring consumables (GC J&W columns, InfinityLab LC columns, Poroshell, ZORBAX, Captiva, Omix, bioreagents), multi-year CrossLab service contracts, software subscriptions, and CDMO service revenue. Distribution combines enterprise field sales with application specialists, an inside-sales request-quote motion, a self-serve e-commerce storefront, country-specific channel partners, OEM arrangements (Hamamatsu), and US Government GSA contracts. Pricing is overwhelmingly quote-based with multi-year contracts across instruments, services, software, and CDMO.

Agilent serves six end markets — Pharmaceutical (~25% of sales), Diagnostics and Clinical, Chemicals and Advanced Materials, Food/Environmental/Forensics, Research and Academia, and Biopharma — with FDA-approved companion diagnostics co-developed with Merck (KEYTRUDA) and Incyte providing regulatory-grade moat. Strategic priorities under the Ignite transformation include AI integration across the stack (Sigsense asset monitoring, OpenAI-BCG enterprise collaboration announced June 2026), $130M in annualized AI-driven manufacturing cost savings, 6.3% Q2 FY26 core revenue growth, 26.4% non-GAAP operating margin, and continued roll-up M&A ($950M Biocare Medical in 2026; $925M BIOVECTRA in 2024). The company has paid dividends for 15 consecutive years.

Name

Agilent Technologies

Legal name

Agilent Technologies, Inc.

Website

https://agilent.com

Company type

Public

Founded year

1999

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Agilent Technologies provides analytical instruments (GC, LC, MS, ICP-MS), pathology and companion diagnostics, software/informatics, consumables, and CDMO services to pharmaceutical, diagnostics, applied chemicals, food/environmental, and academic laboratories across 110 countries, with FY25 revenue of $6.95B.

Ownership category

akta.pro rank

Product category

Analytical Laboratory Instrumentation

NAICS

Analytical Laboratory Instrument Manufacturing (334516), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

Laboratory Analytical Instruments (3826), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Analytical Instruments & Chromatography Systems (HLAGAIAA)

akta.pro secondary industry

mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA) (HLAGAGAC)

Keywords

• Analytical laboratory instruments
• Chromatography and mass spectrometry
• Pathology and diagnostics solutions
• Lab consumables and reagents
• Contract development and manufacturing

Headquarters

HQ city

Santa Clara

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Instrument sales (hardware): Capital equipment revenue from GC, LC, MS, ICP-MS, ICP-OES, FTIR, cell analysis, and digital pathology systems sold to pharma, diagnostics, chemicals, food, environmental, and academic labs. Recurring revenue mix is targeted to expand via non-instrument streams.
2. Consumables, supplies, and reagents: Recurring razor-blade revenue from columns (GC J&W, InfinityLab LC, Poroshell, ZORBAX), sample preparation consumables (Captiva, Omix), chemical standards, syringes, vials, and bioreagents — a major contributor to the durable consumables-and-service revenue base.
3. CrossLab services and support: CrossLab segment generated $759 million in Q2 FY26 with 32.0% operating margin; services and other revenue reached $530 million (up from $482 million a year earlier), covering instrument service plans, asset management, compliance, and CrossLab Connect digital services.
4. Software and informatics subscriptions: Software revenue from OpenLab CDS, MassHunter, CrossLab Connect, iLab, SLIMS, and digital pathology software; positioning as higher-margin recurring software/services stream, expanded via AI-driven product launches such as OpenLab Sync and GC Assist.
5. Specialty CDMO services: Contract development and manufacturing services through Specialty CDMO Services and the BIOVECTRA acquisition (closed September 2024), spanning oligonucleotide GMP manufacturing and advanced therapeutics for mRNA/siRNA/CRISPR pipelines.
6. Companion diagnostic licensing (pharmDx): Royalty and product revenue from FDA-approved companion diagnostics co-developed with pharma partners (e.g., PD-L1 IHC 22C3 pharmDx with Merck for KEYTRUDA); licenses and milestones from pharma collaborations.

Pricing tiers

Go-to-market motion5 records

Distribution channels7 records

Marketing channels10 records

Core offering

Agilent Technologies designs, manufactures, and supports high-precision analytical instruments (gas chromatography, liquid chromatography, mass spectrometry, ICP-MS, FTIR/Raman spectroscopy, cell analysis) together with proprietary software (OpenLab CDS, MassHunter, CrossLab Connect), pathology and companion diagnostics (Dako Omnis, PD-L1 IHC 22C3 pharmDx, S540MD slide scanner), consumables and reagents, and specialty CDMO services for oligonucleotide manufacturing. The company serves pharmaceutical, diagnostics, applied chemicals, food/environmental/forensics, and academic/research laboratories across 110 countries.

Product overview

Agilent Technologies operates a platform-plus-modules portfolio across six key markets (Food, Environmental and Forensics, Pharmaceutical, Diagnostics, Chemicals and Advanced Materials, and Research), spanning core analytical instrument product lines, acquired specialty brands, software/informatics add-ons, and recurring services. The core analytical instrumentation platform comprises the Infinity III LC Series (HPLC/UHPLC), the 8890B/8860B/8850 GC family, the 9500 Triple Quadrupole ICP-MS, molecular spectroscopy (FTIR, Fluorescence, Raman, UV-Vis), cell analysis (Seahorse, RTCA, BioTek), capillary electrophoresis, and GPC/SEC chromatography with acquired Polymer Standards Service (PSS) columns. Mass detection is layered through Agilent LC/MS (including the InfinityLab Pro iQ Series) and the 7010D Triple Quadrupole GC/MS. Clinical and diagnostic modules include the Dako Omnis staining platform, the PD-L1 IHC 22C3 pharmDx companion diagnostic, the new Biocare Medical immunohistochemistry and in situ hybridisation portfolio, the S540MD Slide Scanner System (Agilent-branded Hamamatsu), and Avida Biomed NGS target enrichment workflows. Software & Informatics modules include OpenLab CDS, OpenLab Sync (AI-enabled Lab Execution System integrating USP MethodConnect), MassHunter, iLab, CrossLab Connect (with Sigsense AI asset monitoring), SLIMS, and DakoLink. Specialty CDMO capabilities come via BIOVECTRA (oligonucleotide GMP manufacturing), supported by the SurePrint DNA synthesis platform and Agilent Oligo Pools. Recurring services (CrossLab, instrument service plans, certified pre-owned instruments, compliance consulting) and university programs (ARC, SIRA, AECPA, Thought Leader Awards) wrap around the hardware and software platform to deliver ~$6.95B in FY25 revenue across 110 countries.

Differentiator

Problem solved

Functional benefit

Brands

• CrossLab: Agilent's services and support portfolio spanning instrument service plans, asset management, lab operations software (CrossLab Connect), and consulting.
• OpenLab
• Dako
• InfinityLab
• MassHunter
• J&W
• ZORBAX
• Poroshell
• SurePrint
• iLab
• SLIMS
• Biovectra
• E-MSion
• Polymer Standards Service
• Sigsense

Products and services

• Agilent Infinity III LC Series Modular HPLC and UHPLC systems with InfinityLab Assist for automated startup/shutdown, Level Sensing to prevent dry-running, and Sample ID Reader for automated vial barcode reading; upgrades available for existing Infinity II systems.
• Agilent Gas Chromatography Systems (8890B GC, 8860B GC, 8850 GC) Gas chromatography systems featuring Capillary Flow Technology, self-tightening column nuts, ADM Flow Meter, and Instrument Intelligence (GC Assist) with built-in troubleshooting and remote diagnostics; the 8890B adds up to 30% faster oven cooling.
• Agilent 9500 Triple Quadrupole ICP-MS Next-generation trace elemental analysis instrument with proprietary Dual-Cell System (Air Cell and Advanced Helium Mode) delivering more than 33% reduction in acquisition time vs. traditional single quadrupole systems for environmental, food, pharmaceutical, and advanced materials testing.
• Agilent Liquid Chromatography / Mass Spectrometry (LC/MS) LC/MS solutions including the InfinityLab Pro iQ Series mass detectors for protein and small-molecule mass detection, coupling Agilent HPLC/UHPLC systems with mass spectrometry detectors for proteomics, biopharma, and small-molecule analysis.
• Agilent Gas Chromatography/Mass Spectrometry (GC/MS) GC/MS systems including the 7010D Triple Quadrupole GC/MS (winner of Scientists' Choice Award for Best New Analytical Product of 2024) for trace analysis across environmental, food safety, forensic, and pharmaceutical applications.
• Agilent Cell Analysis (Seahorse, RTCA, BioTek) Cell analysis instruments and software including Seahorse XF analyzers for metabolic analysis, real-time cell analysis (RTCA), and BioTek microplate instrumentation for live-cell and biochemical assays.
• Agilent Molecular Spectroscopy Molecular spectroscopy portfolio including FTIR, Fluorescence, LDIR, Raman, and UV-Vis & UV-Vis-NIR spectroscopy instruments and supplies for material identification and quantification.
• Agilent 1290 Infinity III Fluorescence Detector (FLD) Ultra-high-performance liquid chromatography fluorescence detector offering ultra-trace sensitivity for biopharmaceutical analysis, food safety testing, and environmental monitoring.
• Agilent S540MD Slide Scanner System High-throughput whole-slide imaging digital scanner with capacity for up to 540 slides, automated scanning modes, and AI-assisted tissue detection, now available across Germany, France, Belgium, Spain, Austria, Luxembourg, Italy, UK, and Switzerland under the EU IVDR framework.
• Agilent Digital Pathology Solutions End-to-end digital pathology portfolio spanning staining, slide scanning (S540MD), and AI-based decision support for clinical and research pathology laboratories.
• PD-L1 IHC 22C3 pharmDx FDA-approved immunohistochemistry companion diagnostic co-developed with Merck for identifying patients eligible for KEYTRUDA (pembrolizumab) treatment across NSCLC, head and neck squamous cell carcinoma, esophageal squamous cell carcinoma, triple-negative breast cancer, cervical cancer, and gastric/gastroesophageal junction adenocarcinoma.
• Dako Omnis Panel Agilent's automated IHC staining platform and the only FDA-approved IHC panel for identifying mismatch repair deficient colorectal cancer patients eligible for Opdivo (nivolumab) ± Yervoy (ipilimumab) immunotherapy.
• OpenLab Sync AI-enabled Lab Execution System that digitally connects scientific workflows from method design through bench execution; first integrator of USP MethodConnect, enabling machine-readable USP-NF test method content for pharmaceutical QC and regulated environments.
• OpenLab CDS Chromatography data system bringing LC, LC/MS, and LC high-resolution MS together in a single modern data system for QC labs; supports cloud deployment and remote work and integrates with InfinityLab Assist, Level Sensing, and Sample ID Reader hardware.
• MassHunter Software Mass spectrometry software suite for advanced MS applications covering data acquisition, data analysis, library management, and simplified interfaces.
• CrossLab Connect Lab operations management software integrating Sigsense AI asset monitoring algorithms to monitor and improve instrument performance across labs with large instrument fleets; supports technological refresh planning based on real utilization data.
• Agilent Specialty CDMO Services (BIOVECTRA) Specialty contract development and manufacturing organization services including oligonucleotide GMP manufacturing and advanced therapeutics for mRNA/siRNA/CRISPR pipelines; BIOVECTRA acquired September 2024 for $925M.
• Agilent CrossLab Services & Support Comprehensive instrument services including CrossLab Instrument Service Plans, asset management, method consulting, lab compliance, instrument qualification, software upgrades, installation, relocation, and trade-in/buyback programs; $759M Q2 FY26 revenue at 32% operating margin.
• SurePrint DNA Synthesis Platform Agilent's massively parallel oligo pool synthesis platform for protein engineering and gene assembly applications; currently supports sequences up to 230 nucleotides, with plans to increase to 300 nucleotides in 2026.
• Agilent PFAS Testing Kits Application kits for PFAS testing across environmental, food, and water samples, supporting LC/MS and UHPLC workflows for trace-level analysis.
• Agilent Multi-Attribute Method (MAM) QC Workflow for Biologics Workflow for quality control laboratories in the biopharmaceutical industry supporting regulated testing environments and integrating with existing QC systems to address operational barriers in adopting LC/HRMS techniques.
• Avida Biomed NGS Workflows High-performance next-generation sequencing target enrichment workflows for cancer research, including the Avida Duo system for simultaneous mutation detection and DNA methylation profiling from a single circulating cell-free DNA sample; acquired January 2023.
• Biocare Medical Pathology Solutions Clinical pathology portfolio including immunohistochemistry assays, in situ hybridization (RNA-ISH probes), fluorescence in situ hybridization solutions, staining instruments and reagents, and 300+ specialized antibodies; acquired June 2026 for $950M.
• Polymer Standards Service (PSS) Provider of polymer characterization solutions, expanding Agilent's GPC/SEC product offerings in liquid chromatography and polymer analysis for chemical and biopharmaceutical industries; acquired August 2022.

Quantifiable outcome

• Achieved $130 million in annualized cost savings via the Ignite transformation and AI-driven manufacturing
• +6 more outcomes

Named customers13 records

Segments7 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration5 records

AI capability11 records

Feature10 records

Partnerships

15 partnerships are on record, tiered core, flagship and minor.

• HamamatsucoreOEM/ Whitelabel/ Licensing Partner · 21 June 2026OEM / whitelabel partnership for the Agilent S540MD Slide Scanner System, an Agilent-branded version of the Hamamatsu NanoZoomer S540MD whole-slide imaging scanner. Launched in European markets (Germany, France, Belgium, Spain, Austria, Luxembourg, Italy, UK, Switzerland) under the EU IVDR framework as part of an ongoing partnership, with plans to expand to additional European countries in 2026.
• OpenAIflagshipStrategic or Co-development Partner · 3 June 2026Enterprise-wide AI collaboration announced June 3, 2026 combining Agilent's scientific expertise and data assets with OpenAI's AI research capabilities and BCG's transformation expertise. Expected to accelerate AI deployment across Agilent's products, operations, and customer workflows over 6 to 12 months.
• Boston Consulting Group (BCG)flagshipImplementation/ SI/ Consulting Partner · 3 June 2026Enterprise-wide AI transformation partnership announced June 3, 2026 alongside OpenAI. BCG brings large-scale transformation expertise to build and scale applied AI solutions across Agilent's instruments, software, and customer workflows. BCG has already deployed Agilent AI solutions in production.
• Merck & Co.flagshipStrategic or Co-development Partner · 2 June 2026Co-development partnership for PD-L1 IHC 22C3 pharmDx companion diagnostic on Dako Omnis platform. The FDA-approved test identifies patients eligible for treatment with Merck's KEYTRUDA (pembrolizumab) across multiple cancer types including NSCLC, head and neck squamous cell carcinoma, esophageal squamous cell carcinoma, triple-negative breast cancer, cervical cancer, gastric/GEJ adenocarcinoma, and mismatch repair deficient colorectal cancer.
• Sound AnalyticsminorStrategic or Co-development Partner · 1 June 2026Collaboration announced June 1, 2026 to advance LC/MS workflows for drug metabolism research, combining Agilent's LC/MS expertise with Sound Analytics' analytics capabilities.
• C-CAMP (Centre for Cellular and Molecular Platforms)coreStrategic or Co-development Partner · 12 May 2026Expanded partnership providing Indian researchers and biotech startups access to advanced Agilent drug-testing and mass spectrometry equipment housed at C-CAMP's Bengaluru facility. Phase 1 enabled Indian scientists to fully characterize Liraglutide (a diabetes/obesity drug) to international regulatory standards; Phase 2 expands to biological medicines for cancer, rare diseases, and infectious conditions plus a new training programme.
• LabcorpcoreChannel Partner/ Reseller/ Distributor · 22 April 2026Labcorp launched nationwide availability of Agilent's PD-L1 IHC 22C3 pharmDx companion diagnostic for ovarian cancer patients eligible for pembrolizumab (Keytruda). The test identifies platinum-resistant ovarian cancer patients based on the Phase 3 KEYNOTE-B96 trial outcomes.
• Biocare MedicalflagshipStrategic or Co-development Partner · 9 March 2026$950 million all-cash acquisition announced March 9, 2026 and completed June 25, 2026. Biocare Medical is a global leader in immunohistochemistry and molecular pathology solutions with more than 300 specialized antibodies, offering IHC, in situ hybridization, and fluorescence in situ hybridization assays. Expected to close by Agilent's fiscal Q4 2026 and be accretive to revenue, margins, and EPS within 12 months; Biocare generated over $90M revenue in 2025.
• BIOVECTRAflagshipStrategic or Co-development Partner · 1 September 2024Acquired by Agilent for $925 million in September 2024 to strengthen mRNA therapeutics CDMO and oligonucleotide GMP manufacturing capabilities. Provides specialty CDMO services and contract development/manufacturing capacity for nucleic acid therapeutics.
• Incyte CorporationcoreStrategic or Co-development Partner · 1 January 2024Companion diagnostic development partnership to expand Agilent's companion diagnostics portfolio and support Incyte's oncology and hematology therapies. Early 2024 announcement enabled co-development of diagnostic tests for Incyte's targeted therapies.
• e-MSionminorStrategic or Co-development Partner · 9 March 2023Acquired in March 2023; an early-stage company developing Electron Capture Dissociation (ECD) technology that accelerates drug development. ECD technology is now part of Agilent's LC/MS portfolio.
• Avida BiomedminorStrategic or Co-development Partner · 5 January 2023Acquired by Agilent in January 2023 (reported $30 million consideration) to strengthen next-generation sequencing (NGS) target enrichment workflows for cancer research; Avida's high-performance NGS technology is now part of Agilent's genomics portfolio.
• Polymer Standards Service GmbH (PSS)minorStrategic or Co-development Partner · 2 August 2022Acquired in August 2022; a provider of polymer characterization solutions expanding Agilent's GPC/SEC (Gel Permeation Chromatography / Size Exclusion Chromatography) product offerings in liquid chromatography and polymer analysis for chemical and biopharmaceutical industries.
• Imperial College LondoncoreStrategic or Co-development PartnerLong-term research collaboration via the Agilent Measurement Suite at Imperial College London, providing researchers access to advanced Agilent instruments, expert support, and a vibrant ecosystem fostering transformative scientific progress. Multiple Imperial scientists (e.g., Marina Kuimova) named as Agilent research collaborators.
• Columbia University (Adeyemi Adeleye)minorStrategic or Co-development PartnerAdeyemi Adeleye (Columbia) featured as Agilent customer story for innovative approaches to sustainable environmental cleanup using Agilent instrumentation. Awarded the Agilent Early Career Professor Award in 2024.

Scale indicators15 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• Bio-Techne Corporation: Reagents, proteomics, and diagnostics peer with overlap in academic/research life sciences and ELISA/proteomics workflows — partial overlap with Agilent's cell analysis (Seahorse) and research market consumables.
• Bio-Rad Laboratories: Life science research and clinical diagnostics peer with overlap in NGS workflows, digital PCR, and clinical pathology — adjacent to Avida Biomed's NGS target enrichment and Biocare's pathology portfolio inside Agilent.
• Sartorius AG: Bioprocessing and lab products peer with overlap in biopharma manufacturing — adjacent to Agilent's BIOVECTRA CDMO and bioprocess analytical offerings. Comparable pharma customer base, though Sartorius focuses upstream on bioreactors and filtration.

Broad incumbents

• Danaher Corporation: Diversified life sciences and diagnostics conglomerate owning Beckman Coulter, Cytiva, Leica Biosystems, and SCIEX. SCIEX mass spectrometry and Cytiva bioprocess analytics compete directly with Agilent's mass spec and biopharma offerings; broader portfolio spans diagnostics where Agilent's Dako plays.
• Revvity (formerly PerkinElmer): Post-divestiture life sciences and diagnostics company offering analytical instruments, reagents, software, and diagnostics — overlapping with Agilent in applied markets, food/environmental testing, and reproductive health diagnostics.
• Thermo Fisher Scientific: Largest life sciences tools and analytical instruments peer, competing with Agilent across LC/MS, GC/MS, ICP-MS, chromatography consumables, lab services, and biopharma services. Much broader portfolio (PPD, Patheon, BioProduction) but directly comparable in pharma and applied analytical instrumentation.

Direct peers

• Mettler-Toledo International: Precision instruments peer offering laboratory balances, pipettes, pH meters, and analytical instrumentation overlapping with Agilent's lab productivity and applied markets segments; comparable customer base in pharma, food, and chemicals.
• Shimadzu Corporation: Japanese analytical instrument manufacturer with overlapping GC, LC, LC/MS, GC/MS, FTIR, and UV-Vis product lines. Competes with Agilent in applied markets, environmental testing, food safety, and pharma QC across global accounts.
• Waters Corporation: Closest direct peer in liquid chromatography, mass spectrometry, and informatics. Competes head-to-head in HPLC/UHPLC columns, ACQUITY UPLC systems, and Empower CDS software, with overlapping pharma, academic, and food/environmental customer bases.
• Bruker Corporation: Direct competitor in mass spectrometry (timsTOF, MALDI-TOF), ICP-MS, and molecular spectroscopy. Overlapping presence in pharma/biopharma, proteomics, and academic research; comparable footprint in applied and life science markets.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat7 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/user/agilent
• Facebookfacebook.com/Agilent.Tech
• LinkedInlinkedin.com/company/1526
• Instagraminstagram.com/agilenttechnologies
• Xx.com/agilent

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries6 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A55 records

Investments39 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Agilent Technologies